6-(4-chloro-anilinomethyl)-pteridine-2,4-diamine | 57963-46-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 蝶啶及其衍生物
• 英文名称: 6-(4-chloro-anilinomethyl)-pteridine-2,4-diamine
• 英文别名: 6-[(4-Chloroanilino)methyl]-2,4-pteridinediamine；6-[(4-Chloroanilino)methyl]pteridine-2,4-diamine
• CAS: 57963-46-9
• 化学式: C₁₃H₁₂ClN₇
• 分子量: 301.738
• InChiKey: GQYLDCYVZGDUET-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  116
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  对氯苯胺 、 6-溴乙基-喋啶-2,4-二胺 在 sodium hydroxide 作用下， 以 水 为溶剂， 以85% (255 mg)的产率得到6-(4-chloro-anilinomethyl)-pteridine-2,4-diamine
  参考文献：
  名称：

  6-(Bromomethyl)-2,4-diaminopteridine hydrobromide

  摘要：

  一种具有化学式6-(溴甲基)-2,4-二氨基喹啉盐酸盐的喹啉化合物。2,4-二氨基-6-喹啉甲醇盐酸盐与三苯基膦二溴化物或三溴化磷反应，形成6-(溴甲基)-2,4-二氨基喹啉盐酸盐。然后，分子中的溴原子可以被甲氨基苯甲酰-L-谷氨酸（甲氨基四氢叶酸）或氨基对氨基苯甲酰-L-谷氨酸（氨基四氢叶酸）等功能基团所取代。

  公开号：

  US04077957A1

文献信息

• Lipophilic Antifolates as Agents against Opportunistic Infections. 1. Agents Superior to Trimetrexate and Piritrexim against <i>Toxoplasma gondii</i> and <i>Pneumocystis carinii</i> in <i>in Vitro</i> Evaluations
  作者：James R. Piper、Cheryl A. Johnson、Charles A. Krauth、Ronald L. Carter、Carla A. Hosmer、Sherry F. Queener、Susan E. Borotz、Elmer R. Pfefferkorn

  DOI：10.1021/jm950760y

  日期：1996.3.15

  2,4-Diaminopteridines (21 compounds) and 2,4-diamino-5-methyl-5-deazapteridines (34 compounds) along with three 2,4-diamino-5-unsubstituted-5-dieazapteridines and four 2,4-diaminoquinazolines, each with an aryl group attached to the 6-position of the heterocyclic moiety through a two-atom bridge (either CH2NH, CH2N(CH3), CH2S, or CH2CH2), were synthesized and evaluated as inhibitors of the growth of Toxoplasma gondii in culture and as inhibitors of dihydrofolate reductase enzymes from T. gondii, Pneumocystis carinii, and rat liver. Exceptionally high levels of combined potency and selectivity as growth inhibitors of T. gondii and as inhibitors of the microbial enzymes relative to the mammalian enzyme were found among the 5-methyl-5-deazapteridines but not for the other heterocyclic types. Thirty of the 34 5-methyl-5-deaza compounds gave growth inhibition IC50 values lower than that of pyrimethamine (0.4 mu M) with 14 compounds below 0.1 mu M, values that compare favorably with those for piritrexim and trimetrexate (both near 0.02 mu M). As inhibitors of T. gondii DHFR, all but three of the 34 5-methyl-5-deaza compounds gave IC50 values in the order of magnitude with those of piritrexim (0.017 mu M) and trimetrexate (0.010 mu M), and 17 compounds of this group gave IC50 values versus P. carinii DHFR similarly comparable with those of piritrexim (0.031 mu M) and trimetrexate (0.042 mu M). Thirteen of these congeners gave both T. gondii growth inhibition and DHFR inhibition IC50 values of 0.10 mu M or less, thus indicating facile penetration of the cell membrane. Eleven of these inhibitors of both T. gondii growth and DHFR have selectivity ratios (IC50 rat liver divided by IC50 T gondii) of 5 or greater for the parasite DHFR. The highest selectivity ratio of nearly 100 belongs to the 5-methyl-5-deaza compound whose B-substituent is CH2CH2C6H3(OCH3)(2)-2,5. This compound is over 10(3)-fold more selective for T. gondii DHFR than bridge homologue piritrexim (selectivity ratio 0.088), a compound now in clinical trials. The candidate with CH2NHC6H3(CH3)(2)-2,5 in the 6-position gave the highest P. carinii DHFR selectivity ratio of 4.0, which is about 60-fold more selective than trimetrexate (0.071) and 80-fold more selective than piritrexim (0.048) toward this enzyme. The 10 best compounds with respect to potency and selectivity includes six compounds bearing 2,5-disubstituted phenyl groups in the side chain (with little, if any, difference in effects of methyl, methoxy, or ethoxy), two side chains bearing 1-naphthyl groups, and two with 5,6,7,8-tetrahydro-1-naphthyl groups. Bridge groups represented in the 10 choice compounds are CH2NH, CH2N(CH3), CH2CH2, and CH2S. The high levels of both potency and selectivity among these agents suggest that in vivo studies now underway may lead to agents that could replace trimetrexate and piritrexim in treatment of toxoplasmosis and P. carinii pneumonia.
• MONTGOMERY J. A.; PIPER J. R.; ELLIOTT R. D.; ROBERTS E. C.; TEMPLE C.; S+, J. HETEROCYCL. CHEM., 1979, 16, NO 3, 537-539
  作者：MONTGOMERY J. A.、 PIPER J. R.、 ELLIOTT R. D.、 ROBERTS E. C.、 TEMPLE C.、 S+

  DOI：——

  日期：——
• US4077957A
  申请人：——

  公开号：US4077957A

  公开（公告）日：1978-03-07
• US4079056A
  申请人：——

  公开号：US4079056A

  公开（公告）日：1978-03-14
• 6-(Bromomethyl)-2,4-diaminopteridine hydrobromide
  申请人：The United States of America as represented by the Department of Health,

  公开号：US04077957A1

  公开（公告）日：1978-03-07

  A pteridine compound having the formula of 6-(bromomethyl)-2,4-diaminopteridine hydrobromide. 2,4-diamino-6-pteridine-methanol.HBr is reacted with triphenylphosphine dibromide or phosphorus tribromide to form 6-(bromomethyl)-2,4-diaminopteridine hydrobromide. The bromine atom in the molecule can then be replaced with the functional group, N-[4-(methylamino)-benzoyl]-L-glutamic acid in the case of methotrexate and N-(4-aminobenzoyl)-L-glutamic acid in the case of aminopterin.

  一种具有化学式6-(溴甲基)-2,4-二氨基喹啉盐酸盐的喹啉化合物。2,4-二氨基-6-喹啉甲醇盐酸盐与三苯基膦二溴化物或三溴化磷反应，形成6-(溴甲基)-2,4-二氨基喹啉盐酸盐。然后，分子中的溴原子可以被甲氨基苯甲酰-L-谷氨酸（甲氨基四氢叶酸）或氨基对氨基苯甲酰-L-谷氨酸（氨基四氢叶酸）等功能基团所取代。